Literature DB >> 25917594

Continuous intravenous infusion of ATP in humans yields large expansions of erythrocyte ATP pools but extracellular ATP pools are elevated only at the start followed by rapid declines.

Eliezer Rapaport1, Anna Salikhova, Edward H Abraham.   

Abstract

The pharmacokinetics of adenosine 5'-triphosphate (ATP) was investigated in a clinical trial that included 15 patients with advanced malignancies (solid tumors). ATP was administered by continuous intravenous infusions of 8 h once weekly for 8 weeks. Three values of blood ATP levels were determined. These were total blood (erythrocyte) and blood plasma (extracellular) ATP pools along with the initial rate of release of ATP into the blood plasma. We found that values related to erythrocyte ATP pools showed great variability (diversity) among individuals (standard deviation of about 30-40% of mean at baseline). It was discovered that erythrocyte baseline ATP pool sizes are unique to each individual and that they fall within a narrow range in each individual. At the end of an 8 h continuous intravenous infusion of ATP, intracellular erythrocyte ATP pools were increased in the range of 40-60% and extracellular ATP declined from elevated levels achieved at the beginning and middle of the infusion, to baseline levels. The ability of erythrocytes to sequester exogenously administered ATP to this degree, after its initial conversion to adenosine in the blood plasma is unexpected, considering that some of the adenosine is likely to have been degraded by in vivo catabolic activities or taken up by organs. The data suggest that administration of ATP by short-term intravenous infusions, of up to 4 h, may be a favorable way for elevating extracellular ATP pools. A large fraction of the total exogenously administered ATP is sequestered into the intracellular compartments of the erythrocytes after an 8 h intravenous infusion. Erythrocytes loaded with ATP are known to release their ATP pools by the application of previously established agents or conditions applied locally or globally to circulating erythrocytes. Rapid degradation of intravenously administered ATP to adenosine and subsequent accumulation of ATP inside erythrocytes indicate the existence of very effective mechanisms for uptake of adenosine from blood plasma. These in vivo studies offer an understanding as to how both adenosine and ATP can act as purinergic transmission signals. ATP levels in blood are always accompanied by adenosine formed by catabolism of ATP. The continuous uptake of adenosine enables both to act in transmission of sometimes opposite functions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25917594      PMCID: PMC4425716          DOI: 10.1007/s11302-015-9450-y

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  36 in total

Review 1.  Intracellular convection, homeostasis and metabolic regulation.

Authors:  P W Hochachka
Journal:  J Exp Biol       Date:  2003-06       Impact factor: 3.312

Review 2.  International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update.

Authors:  Bertil B Fredholm; Adriaan P IJzerman; Kenneth A Jacobson; Joel Linden; Christa E Müller
Journal:  Pharmacol Rev       Date:  2011-02-08       Impact factor: 25.468

3.  Identification and characterization of a novel hepatic canalicular ATP diphosphohydrolase.

Authors:  J Sévigny; S C Robson; E Waelkens; E Csizmadia; R N Smith; R Lemmens
Journal:  J Biol Chem       Date:  2000-02-25       Impact factor: 5.157

4.  Growth inhibition of human tumor cells in soft-agar cultures by treatment with low levels of adenosine 5'-triphosphate.

Authors:  E Rapaport; R F Fishman; C Gercel
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

5.  CD39 is an ecto-(Ca2+,Mg2+)-apyrase.

Authors:  T F Wang; G Guidotti
Journal:  J Biol Chem       Date:  1996-04-26       Impact factor: 5.157

6.  Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnia.

Authors:  G R Bergfeld; T Forrester
Journal:  Cardiovasc Res       Date:  1992-01       Impact factor: 10.787

7.  Anticancer activities of adenine nucleotides in mice are mediated through expansion of erythrocyte ATP pools.

Authors:  E Rapaport; J Fontaine
Journal:  Proc Natl Acad Sci U S A       Date:  1989-03       Impact factor: 11.205

8.  The multidrug resistance (mdr1) gene product functions as an ATP channel.

Authors:  E H Abraham; A G Prat; L Gerweck; T Seneveratne; R J Arceci; R Kramer; G Guidotti; H F Cantiello
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

9.  Cystic fibrosis hetero- and homozygosity is associated with inhibition of breast cancer growth.

Authors:  E H Abraham; P Vos; J Kahn; S A Grubman; D M Jefferson; I Ding; P Okunieff
Journal:  Nat Med       Date:  1996-05       Impact factor: 53.440

10.  ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy.

Authors:  Yuting Ma; Sandy Adjemian; Heng Yang; João Paulo Portela Catani; Dalil Hannani; Isabelle Martins; Mickaël Michaud; Oliver Kepp; Abdul Qader Sukkurwala; Erika Vacchelli; Lorenzo Galluzzi; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2013-04-16       Impact factor: 8.110

View more
  6 in total

Review 1.  ISSN exercise & sports nutrition review update: research & recommendations.

Authors:  Chad M Kerksick; Colin D Wilborn; Michael D Roberts; Abbie Smith-Ryan; Susan M Kleiner; Ralf Jäger; Rick Collins; Mathew Cooke; Jaci N Davis; Elfego Galvan; Mike Greenwood; Lonnie M Lowery; Robert Wildman; Jose Antonio; Richard B Kreider
Journal:  J Int Soc Sports Nutr       Date:  2018-08-01       Impact factor: 5.150

2.  Cystic fibrosis improves COVID-19 survival and provides clues for treatment of SARS-CoV-2.

Authors:  Edward H Abraham; Guido Guidotti; Eliezer Rapaport; David Bower; Jack Brown; Robert J Griffin; Andrew Donnelly; Ellen D Waitzkin; Kenon Qamar; Mark A Thompson; Sukumar Ethirajan; Kent Robinson
Journal:  Purinergic Signal       Date:  2021-05-10       Impact factor: 3.765

Review 3.  Historical and Current Adenosine Receptor Agonists in Preclinical and Clinical Development.

Authors:  Kenneth A Jacobson; Dilip K Tosh; Shanu Jain; Zhan-Guo Gao
Journal:  Front Cell Neurosci       Date:  2019-03-28       Impact factor: 5.505

4.  ATP-loaded biomimetic nanoparticles as controlled release system for extracellular drugs in cancer applications.

Authors:  Patricia Díaz-Saldívar; Juan Pablo Huidobro-Toro
Journal:  Int J Nanomedicine       Date:  2019-04-05

5.  ATP promotes immunosuppressive capacities of mesenchymal stromal cells by enhancing the expression of indoleamine dioxygenase.

Authors:  Ramin Lotfi; Lena Steppe; Regina Hang; Markus Rojewski; Marina Massold; Bernd Jahrsdörfer; Hubert Schrezenmeier
Journal:  Immun Inflamm Dis       Date:  2018-10-10

Review 6.  Extracellular ATP: A Feasible Target for Cancer Therapy.

Authors:  Valentina Vultaggio-Poma; Alba Clara Sarti; Francesco Di Virgilio
Journal:  Cells       Date:  2020-11-17       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.